





Administration of RSV vaccines and RSV monoclonal antibodies by age group or cohort

Age group or cohort	RSV vaccines for adults		RSV monoclonal antibodies for Infants	
	Abrysvo® 0.5ml (Pfizer) 	Arexvy® 0.5 mL (GSK) 	Beyfortus™ (Nirsevimab) 0.5 mL (Purple) (Sanofi) 	Beyfortus™ (Nirsevimab) 1 mL (Blue) (Sanofi) 
Pregnant women at 28 to 36 weeks	NIP FUNDED	DO NOT USE	DO NOT USE	DO NOT USE
Infants & children <24 months	DO NOT USE	DO NOT USE	STATE & TERRITORY FUNDED	STATE & TERRITORY FUNDED
People aged ≥50 years with medical risk factors	DO NOT USE	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION*	DO NOT USE	DO NOT USE
All people aged ≥60 years (including Aboriginal and Torres Strait Islander people)	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION	AVAILABLE PRIVATELY BASED ON CLINICAL DECISION*	DO NOT USE	DO NOT USE

Note: **NIP FUNDED** indicates vaccine is NIP funded. **DO NOT USE** indicates that the vaccine is **NOT** recommended to be used by that age group. **STATE & TERRITORY FUNDED** indicates that it is funded under a state and territory Immunisation program. *Funded under some state and territory programs. For state and territory eligibility, refer to the state or territory's immunisation schedule. **AVAILABLE PRIVATELY** indicates this product is only available through private prescription and is not subsidised under the NIP. For further information including dosage and administration, refer to the Australian Immunisation Handbook chapter – [Respiratory syncytial virus \(RSV\)](#).